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HIV-reservoirt minimum productive HIV infection in astrocytes (a predominant cell type in
brain and persists for the entire life) occurs through endocytosis. The lysosomotropic agent chloroquine
enhanced permissiveness of astrocytes to HIV infection possibly by circumventing degradation of endosome-
entrapped viral particles. In particular, chloroquine may promote establishment of a stable long term viral
reservoir in astrocytes and may eventually facilitate early onset of neurological complications.
© 2008 Elsevier Inc. All rights reserved.IntroductionHIV infection of the brain may lead to cognitive and motor im-
pairment and may eventually cause a dementing illness. The brain is
also an important reservoir for HIV where it resides in macrophages/
microglia and astrocytes. The life cycle of the HIV in these two cell
types is different. In macrophages, HIV enters through a pH-
independent pathway using the CD4-receptor and coreceptor either
CCR5 or CXCR4, leading to fusion mediated viral entry (Fackler and
Peterlin, 2000). In astrocytes, the mechanism of HIV entry is not
completely understood; however, it is known to be independent of
CD4-receptor (Tornatore et al., 1994) and is shown to be via endo-
cytosis leading to minimum productive infection (Li et al., 2007). This
mode of viral entry is also used for productive infection by other
enveloped viruses (Chandran et al., 2005).
Chloroquine is known to have a profound inﬂuence on endosomes
and causes reprogramming of endosomal pH (Maxﬁeld, 1982; Wei
et al., 2005). It is also widely used as an anti-malarial drug in regions
of the world where HIV and malaria are co-existent. Chloroquine
(10–25 μM) has been shown to confer a weak anti-HIV activity outside
the range of physiological concentrations by disrupting the glyco-
sylation of gp120 (Rayne et al., 2004; Naarding et al., 2007). None the
less, some reports have demonstrated no beneﬁcial effect of chlor-
oquine and instead have shown increased HIV infection in vitro and a
more severe form of disease outcome in brain with upregulation of
viral replication of other neurotropic viruses (Kamya et al., 2001; Seth
et al.,1999). Given their high endocytic activity forHIV particles (Clarkean).
l rights reserved.et al., 2006; Deiva et al., 2006), in the present studywe investigated the
impact of chloroquine on HIV infection in neuro-glial cells.
Results and discussion
Human fetal astrocytes (HFA) from aborted fetuses of 8–10 weeks
age were obtained according to institutional guidelines and were
cultured in 6–24 wells culture plates as described earlier (Chauhan et
al., 2007). The HFA were infected with recombinant HIV (NLENY1)
containing an YFP-gene inserted between the nef and env viral genes
(Kutsch et al., 2002). The virus was prepared in 293-T cells upon
transfection of either NLENY1 DNA alone or in combination with
VSV-G expression plasmid followed by collection of supernatants after
72 h and treatment with 100 U of RNase free DNase for 20 min at RT
(Chauhan et al., 2007). The toxicity dose response concentrationswere
from 0–500 μM (Fig. 1) and concentrations at or above 12.5 μM were
found to be toxic on HFA in 24–48 h of treatments. The plasma
concentrations of chloroquine is 0.1 μM while in lung, heart and
kidneys is 200 times and in brain is 10–30 times of plasma levels with
a half life of 7–10 days. Hence, chloroquine was used within the
physiological range achievable in brain. Following treatment with
chloroquine (0–5 μM) for 2 h either pre- or post-HIV infection, HFA
cultures were monitored for infection. However, 5 μM concentration
was found to be toxic in long term culture treatments as well as was
outside the physiological limit. To keep the concentration within
upper physiological range (brain), chloroquine was used at 2.5 μM
without any toxicity in all the experiments either short term (2 h) or
long term (4–21 days). In parallel as controls, HIV infection studies
were performed on HFA using a speciﬁc lysosomotropic agent
Baﬁlomycin-A. The infection was followed up for 3 weeks, a time
Fig. 1. Dose response effect (toxicity) of lysosomotropic agents on primary astrocytes.
Primary human astrocytes (HFA) were seeded in 48 wells tissue culture plate and tested
for toxicity of Baﬁlomycin-A and chloroquine in a dose dependent manner. The toxicity
was monitored by quantitative cell viability assay system after 48 h in quadruplicate
using nitro-propionic acid (8 nM 3) as a positive control.
Fig. 2. HIV infection of astrocytes with lysosomotropic agents. (A: a), HFA infected with HIV
immunostaining; (c), control HFA under green ﬁlter; (d), panel (c) showing GFAP positivity;
for 2 h ) with a light phase view in (f); (g), HIV-NLENY1-infected lymphocytic cells show
lymphocytes near leaf like infected astrocyte (green) on 8 days post co-culture; (h) control HF
uninfected Jurkat cells as controls; (k) HFA infected with VSV-NLENY1 virus 4 dpi and (l) u
lysosomotropic agents, chloroquine (chloro, 2.5 μM) and baﬁlomycin-A (Baﬁl, 100 nM) andm
in HIV infection of astrocytes. Single infected astrocyte from chloroquine-untreated cultures
with chloroquine and baﬁlomycin or in combination. Minocycline does not affect endosom
region from YU-2) virus infection in HFA: NLENV3Y1 infection of astrocytes in the presenc
infected astrocytes) in 27 days of follow-up (n=5).
2 Rapid Communicationperiod based on our previous HIV infection baseline studies on neuro-
glial cells (Chauhan et al., 2007; Chauhan et al., unpublished]. The
HIV-infected astrocytes were tracked and counted by YFP-ﬂuores-
cence every 5 days. The supernatants collected at various times
were analyzed quantitatively for viral replication by p24 assay
(ZeptoMetrix Corp., NY, USA). The HIV-infected cells were iden-
tiﬁed as astrocytes upon immunostaining using monoclonal anti-
body to GFAP (Sigma, USA), a marker for astrocytes. The HIV
NLENY1-infected Jurkat cells were used as controls to compare the
overall infection.
An extremely low level of productive infection (less than 0.025%)
by HIV-NLENY1 virus was observed in HFA compared to Jurkat cells
(Fig. 2A). Intriguingly, upon chloroquine treatment, a several fold (15–
20 folds) increase in HIV infection in a dose dependent manner (data
only shown for 2.5 μM concentration) was observed in comparison to
untreated but infected astrocytes (Figs. 2A and B). In parallel with
chloroquine and baﬁlomycin-A, minocycline was used as a control
which does not interfere in endocytosis and endosomal pH.
Minocycline has shown to confer anti-HIV activity. In our experi-
ments minocycline was not expected to show any inhibitory effects-NLENY1 showing infected astrocyte; (b), infected astrocytes in (a) with GFAP marker
(e), showing HIV-infected HFA in the presence of 2.5 μM chloroquine (chloro, treatment
ing trans-infection in astrocytes upon co-culture, infected (ﬂuorescent) small round
A co-cultured with normal lymphocytes; (i) Jurkat cells infectedwith NLENY1 (6 dpi); (j)
ninfected control HFA cells. (B) HIV-NLENY1 infection of astrocytes in the presence of
inocycline [Mino, 25 μg/ml] (n=3): Lysosomotropic agents revealed several fold increase
is shown in insert. Minocycline treatment for 2 h serves as a negative control in parallel
al pH or endocytosis. (C) Effect of lysosomotropic agents on NLENV3Y1 (hybrid R5, V3
e of chloroquine revealed 12–25 fold increase in HIV infection (compared to untreated
Fig. 3. Effect of lysosomotropic agents either on persistently NLENY1 (X4) infected
astrocytic cells (SVGA) or on HIV-LTR promoter in latently monocytic (THP) p89GFP
(dual tropic) cells reactivated with TNF-α. (A) Baﬁlomycin (100 nM) and chloroquine
(2.5 μM) profoundly increased HIV replication (p24) in persistently infected astrocytic
cells for 4 days (n=3). Further, long term treatment with minocycline revealed
signiﬁcant anti-HIV activity on persistently infected astrocytes, however, on combina-
tion with lysosomotropic agents could not attenuate the enhanced HIV replication by
chloroquine or baﬁlomycin. (B) Effect of chloroquine and baﬁlomycin-A (same con-
centrations as shown above) on HIV-LTRGFP reporter cells: THP89 cells latently infected
with p89.6GFP virus (dual tropic) were treated with chloroquine and baﬁlomycin-A for
48 h. Both the drugs failed to induce reactivation of latent HIV compared to TNF-α
(positive control). Control cells did not reveal green ﬂuorescence above background
levels.
3Rapid Communicationon HIV infection of astrocytes in 2 h of treatment (either preinfection
or post infection treatments). Indeed, minocycline treatment (25 μg/
ml) alone or in combination with chloroquine (2.5 μM) did not show
any interfering effect on chloroquine enhanced HIV infection in
astrocytes (Fig. 2B). The peak infection in either untreated or
chloroquine/baﬁlomycin-A treated HIV-infected astrocytes was seen
between 10–15 days post infection (Figs. 2A and B) compared to
lymphocytes (peak HIV infection at 6–8 days, Fig. 2AI). In contrast,
NLENV3Y1-(hybrid R5)-virus (brain derived R-tropic YU-2 strain V3-
envelope region engineered in NLENY1 backbone deﬁcient in its own
V3 region) revealed incredibly weak infection in HFA; but, chlor-
oquine treatment resulted in similar degree of increase in HIV
infection as seenwith NLENY1 (X4)-infected chloroquine-treated HFA
(Fig. 2C), indicating endocytosis mediated viral entry (chloroquine
prevented viral particles degradation in lysosomes) irrespective of
viral envelope (CD4- and CXCR4-independent infection, manuscript
in preparation). Besides, nonspeciﬁc effects such as release of residual
virus without viral replication by astrocytes (Clarke et al., 2006) upon
treatment with these agents, was ruled out by the cumulative
evidence of rescuing of infectious virus from these chloroquine-
treated HIV-infected astrocyte cultures by trans-infection of lympho-
cytes or vice versa (Fig. 2A-g, detailed manuscript in preparation),
YFP-gene expression (Figs. 2A–C) and HIV genome integration (Fig.
2D). This indicated that low HIV infection in astrocytes is productive
and through integrated viral DNA but not merely by unintegrated
viral DNA. Hence, to corroborate further elevated viral infection and
to implicate invigorating-synergism between HIV and chloroquine,
we monitored the effect of chloroquine on either acutely VSV-
NLENY1 (HIV pseudotyped with VSV-G envelope) infected or
persistently infected astrocytes clonally obtained after infection.
Neither chloroquine nor Baﬁlomycin-A, were able to inhibit wild
type HIV replication in persistently infected astrocytes when
compared to minocycline, instead enhanced p24 expression was
observed (Fig. 3A). Similar to our observations, baﬁlomycin-A recently
has been shown to elevate HIV infection in astrocytes (Deiva et al.,
2006). Since long term treatment with minocycline revealed
signiﬁcant anti-HIV activity on persistently infected astrocytes,
however, on combination with lysosomotropic agents could not atte-
nuate the enhanced HIV permissiveness of astrocytes by chloroquine
or baﬁlomycin (Fig. 3A). In contrast, lysosomotropic agents revealed
strong antiviral effect on acute VSV-pseudotyped HIV-infected
astrocytes suggesting the inhibitory activity on pH-dependent viral
endocytosis entry (VSV enters through pH depedent endocytosis)
(manuscript in preparation). However, it is still ambiguous whether
the presence of chloroquine during HIV infection of astrocytes has
any additional effects other than lysosomotropic effect. Subsequently,
these lysosomotropic agents in our further investigations did not
show any stimulatory effect on the HIV-LTR promoter in latently HIV-
89ENG (dual-tropic virus p89.6 virus genetically engineered with GFP
gene) infected monocytic cells (Fig. 3B) and HIV-LTR-GFP astrocytic
cells (unpublished).
Our study unambiguously shows that chloroquine profoundly
increases the permissivity of neuro-glial cells to HIV infection. In the
pH-dependent pathway, the acidic environment of endosomes is
used for release of viral nucleocapsids into the cytoplasm for viral
replication. Therefore, lysosomotropic agents will block productive
viral replication in a pH-dependent viral entry route. However, in a
pH-independent viral entry route, viral replication will be unaffected
by these agents. Albeit, when pH-independent viruses (such as HIV)
enter through pH-dependent route via endocytosis in the absence of
viral receptors, endocytosed viral particles will be ﬂagged for
degradation pathway (Fig. 4). However, the application of lysosomo-
tropic agents may molecularly tune the astrocytes for efﬁcient
release of entrapped viral nucleocapsids from endosomes (without
degradation) and subsequently lead to more number of viral-DNA
copies integration. This will lead to enhanced productive HIV infec-tion (Fig. 4) (Fackler and Peterlin, 2000; Wei et al., 2005; Chauhan et
al., manuscript in preparation). Similarly, a study by Clarke et al.
(2006) has demonstrated that astrocytes uptake sufﬁcient number of
HIV particles via phagocytosis/macropinocytosis without viral repli-
cation and subsequent lysosome-mediated degradation or release of
undegraded viral particles to the extracellular environment by an
unknown mechanism. This study however, could not demonstrate
viral integration which possibly may be due to natural weak infection
of astrocytes in contrast to present study wherein lysosomotropic
agents have facilitated the rate of viral infection several fold (Figs. 2
and 3).
Hence, our observations led to a conjecture that chloroquine
potently strengthens the endocytosis mediated productive HIV
infection in non-CD4 positive astrocytes through reprogramming of
endosomal pH, which otherwise without chloroquine would be
minimally productive (Figs. 2–4). Inadvertently, chloroquine-
mediated permissiveness of neuro-glial cells may have serious
consequences in HIV infection of the brain, especially in endemic
Fig. 4. Diagrammatic representation of natural or conditional (under the inﬂuence of lysosomotropic agents) HIV life cycle in human astrocytes: (1) Natural HIV entry route in
astrocytes (in the absence of CD4-receptor) via endocytosis is least productive as viral particles may be degraded in the endosomes. Possibly few intact viral nucleocapsids will be
released from the endosomes and would establish minimum infection. (2) Induced or conditional HIV entry route under the inﬂuence of lysosomotropic agents (chloroquine or
Baﬁlomycin-A): Lysosomotropic agents will reprogram the endosomal pH and would result in release of more viral nucleocapsids. The higher number of released viral nucleocapsids
will lead to more events of viral-DNA integration and subsequently more productive HIV infection.
4 Rapid Communicationareas with malarial co-infection where this drug is more commonly
prescribed. In particular, chloroquine may promote early develop-
ment of neurological complications and establishment of a stable
long term reservoir of HIV in otherwise non-permissive long lived
neuro-glial cells. Indeed, besides its impuissance in curtailing HIV
infection of the brain, chloroquine could be useful in inhibition of
other enveloped viral infections that have a pH-dependent entry
route.
Materials and methods
Primary human fetal brain cell culture and cell lines
Primary human fetal astrocytes were cultured from human fetal
tissues as described earlier (Chauhan et al., 2007). Human fetal brain
specimens were obtained from fetuses of 8–14 weeks gestational
age. Brieﬂy, the brain tissue was mechanically dissociated in Opti-
MEM with 5% heat inactivated fetal bovine serum (FBS) and
antibiotic solution (penicillin G 104 U/ml, streptomycin 10 mg/ml,
and amphotericin B 25 μg/ml). The dissociated cells (without trypsin)
were cultured either in Opti MEM (0.2% N2 supplement,) for neurons
or for astrocytes in Dulbecco's modiﬁed Eagle medium (DMEM) with
10% FBS and antibiotics for at least 1 month prior to use in
experiments. Further, after 8 weeks in culture, HFA after 3 rd or 4th
passage were used in experiments. The cultures were veriﬁed for
purity using GFAP, MAP-2 and CD68 markers and no contamination
of microglia but rarely few neurons were observed. SVGA (a human
astrocytic cells sub-clone of the SVG cells), were maintained in
DMEM supplemented with 2 mM L-glutamine, 10% FBS, and
antibiotic solution. Jurkat and 293T cells were grown in RPMI-1640
supplemented with 10% FBS. The astrocytes viability in lysosomo-
tropic agents (chloroquine and baﬁlomycin-A both from Sigma, St.
Louis, USA) was monitored by Cell Quant-Blue Cell viability assay kit
(BioAssay Systems, Hayward, CA,). The cells after treatments with
lysosomotropic agents were incubated with the dye for 3 h and readin a spectrophotometer (Molecular devices) using 530 nM excitation
and 590 nM emission ﬁlters and relative ﬂuorescent units were
plotted.
Viral constructs and plasmids
The green reporter HIV-proviral DNA construct was created by
inserting YFP gene between viral envelope and nef genes without
impairing the HIV open reading frames as reported earlier (Kutsch et
al., 2002). VSV-G expression vector; HIV-proviral DNA pNL4-3 and
pNLE-R+ proviral infectious DNA were obtained from NIAIDS reagent
facility (NIH, USA).
Virus infection
Primary human fetal astrocytes (HFA), lymphocytic cells (Jurkat)
and astrocytic cells (SVGA) were used in infection studies. NL-4–3,
NL-EN-Y1, NLENV3Y1 and VSV-pseudotyped HIV viral stocks were
prepared by transfection of 293T cells using 10–15 μg of plasmids in
100 mm dishes. Virus inoculum containing from 30–1000 ng/ml was
used for infection of lymphocytes and astrocytes. Treatment of HIV-
infected HFA with lysosomotropic agents was performed in 6 well
tissue culture plates with 50,000–75,000 astrocytes (HFA) in each
well and on third day post culture treated with either chloroquine or
Baﬁlomycin-A, for 2 h (2.5 μM) and then infected with HIV for 2 h.
Inoculum was washed 2 times with medium and chloroquine added
again from 4 h to 4 days, and cultures were followed up for 2–3
weeks by monitoring green ﬂuorescence and p24 levels by ELISA
(ZeptoMetrix Corp., NY, USA). Data from experiments were ex-
pressed as mean±SEM. Multiple infection and transfection experi-
ments (more than 5 times) were performed to draw the inference.
Latent viral reactivation studies were performed on monocytic
THP89GFP cells with chloroquine and baﬁlomycin-A using TNF-α
as a positive and minocycline (only 2 h treatment) as negative
controls.
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Viral integration in HIV-infected astrocytes was monitored by Alu-
HIV-LTR PCR (Clarke et al., 2006). The following primer sequences
were used: First round of Alu- PCRwas performed by primers INT-1, 5′-
TGCTGGGATTACAGG GCGTGAG-3′ and INT-2, 5′-TAGACCAGATC-
TGAGCCTGGGA-3′ using following program: 96 °C/3 min [96 °C/45 s,
60 °C/15 s, 72 °C/59 s] 35 cycles and extension 72 °C/7 min. In the
second round 5 μl products from ﬁrst ampliﬁcation were ampliﬁed
using primers INT-N1, 5′-GGCTAACTAGGGAAC-CCACTG-3′ and INT-N9,
5′-CTGCTAGAGATTTTCCACACTGAC-3′ with the following cycle pro-
gram: 96 °C/3 min [96 °C/45 s, 60 °C/15 s, 72 °C/45 s] 35 cycles and
extension 72 °C/7 min.
Immunoﬂuorescence
The infected astrocytes were ﬁxed in 2% paraformaldehyde (PBS) for
15 min and permeablized with 0.2% Triton-X-100 (PBS) for 11 min
followed by blocking with 5% BSA (PBS) for 1 h at room temperature
(25 °C) (Chauhan et al., 2003). The treated cells were overlaid with
primary antibodies at optimum working dilutions (anti GFAP and anti
MAP-2 at 1/500 dilutions, Sigma, St Louis, USA) in a moist chamber at
4 °C overnight. After washing ﬁve times with PBS (10 min each, 37 °C),
the secondary antibodies (Molecular probes) labeled either with Alexa
568 or 488 (1/500 dilutions) were added to the specimens for 35min at
25 °C. Subsequently, the specimens were washed four times with PBS,
stained with DAPI (PBS) during the last washing for 10 min and ﬁnally
rinsedwith PBSandmountedwithanti fading agent (biomeda, CA,USA).
The stained specimens were stored at 4 °C or −20 °C until examined.
The specimens were visualized under UV microscope (Nikon) using
single or double ﬁlters and images were captured with CCD camera.
Acknowledgments
We thank Drs. D. Levy (New York University) for NLENY1 and
NLENV3Y1constructs and J. Patton (University of South Carolina) for
the discussions. This study was funded by NIH-grants R01NS050064
to AC and P01MH070306 to AN.References
Chandran, K., Sullivan, N.J., Felbor, U., Whelan, S.P., Cunningham, J.M., 2005. Endosomal
proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308,
1643–1645.
Chauhan, A., Hahn, S., Gartner, S., Pardo, C.A., Netesan, S.K., McArthur, J., Nath, A.,
2007. Molecular programming of endothelin-1 in HIV-infected brain: role of
Tat in up-regulation of ET-1 and its inhibition by statins. FASEB. J. 21,
777–789.
Chauhan, A., Turchan, J., Pocernich, C., Bruce-Keller, A., Roth, S., Butterﬁeld, D.A., Major,
E.O., Nath, A., 2003. Intracellular human immunodeﬁciency virus Tat expression in
astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant
sites via axonal transport. J. Biol. Chem. 278, 13512–13519.
Clarke, J.N., Lake, J.A., Burrell, C.J., Wesselingh, S.L., Gorry, P.R., Li, P., 2006. Novel pathway
of human immunodeﬁciency virus type 1 uptake and release in astrocytes. Virology
348, 141.
Deiva, K., Khiati, A., Hery, C., Salim, H., Leclerc, P., Horellou, P., Tardieu, M., 2006. CCR5,
DC-SIGN-depedent endocytosis and delayed reverse transcription after human
immunodeﬁciency virus type 1 infection in human astrocytes. AIDS Res. Hum.
Retroviruses 22, 1152–1161.
Fackler, O.T., Peterlin, B.M., 2000. Endocytic entry of HIV-1. Curr. Biol. 10, 1005–1008.
Kamya, M.R., Kigonya, C.N., McFarland, W., 2001. HIV infection may adverselyaffect
clinical response to chloroquine therapy for uncomplicated malaria in children.
AIDS 15, 1187–1188.
Kutsch, O., Benveniste, E.N., Shaw, G.M., Levy, D.N., 2002. Direct and quantitative single-
cell analysis of human immunodeﬁciency virus type 1 reactivation from latency.
J. Virol. 76, 8776–8786.
Li, J., Bentsman, G., Potash, M.J., Volsky, D.J., 2007. Human immunodeﬁciency virus type
1 efﬁciently binds to human fetal astrocytes and induces neuroinﬂammatory
responses independent of infection. BMC Neuroscience 8, 31.
Maxﬁeld, F.R., 1982. Weak bases and ionophores rapidly and reversibly raise the pH of
endocytic vesicles in cultured mouse ﬁbroblasts. J. Cell Biol. 95, 676–681.
Naarding, M.A., Baan, E., Pollakis, G., Paxton, M.A., 2007. Effect of chloroquine on
reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to
CD4 positive T-lymphocytes. Retrovirology 30, 4–6.
Rayne, F., Vendeville, A., Bonhoure, A., Beaumelle, B., 2004. The ability of chloroquine
to prevent tat-induced cytokine secretion by monocytes is implicated in it's
in-vivo anti-human immunodeﬁciency virus type 1 activity. J. Virol. 78 (21),
12054–12057.
Seth, P., Mani, H., Singh, A.K., Banaudha, K.K., Madhavan, S., Sidhu, G.S., Gaddipati, J.P.,
Vogel, S.N., Maheshwari, R.K., 1999. Acceleration of viral replication and up-
regulation of cytokine levels by antimalarials: implications in malaria-endemic
areas. Am. J. Trop. Med. Hyg. 61, 180–186.
Tornatore, C., Meyers, K., Atwood, W., Conant, K., Major, E., 1994. Temporal patterns
of human immunodeﬁciency virus type 1 transcripts in human fetal astrocytes.
J. Virol. 68, 93–102.
Wei, B.L., Denton, P.W., O'Neill, E., Luo, T., Foster, J.L., Garcia, J.V., 2005. Inhibition of
lysosome and proteosome function enhances human immunodeﬁciency virus type
1 infection. J. Virol. 79, 5705–5712.
